(redirected from nucleoside analogue)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
References in periodicals archive ?
To determine the absolute risk of MI among nucleoside analogue users, the investigators incorporated the Framingham predicted 10-year coronary heart disease risk into the main regression model, and determined that the rate of MI was increased by 119% in patients with a moderate 10-year risk and by 222% in patients with a high 10-year risk, relative to those with a low 10-year risk, Dr.
Only patients with severe acute HBV infection warrant nucleoside analogue treatment, as more than 95% of immunocompetent patients with acute HBV recover.
Adults: The recommended dosage of SUSTIVA is 600 mg orally, once daily, in combination with a protease inhibitor and/or nucleoside analogue reverse transcriptase inhibitors (NRTIs).
The Company's pipeline includes FV-100, its clinical-stage oral nucleoside analogue in development for the treatment of herpes zoster (shingles), as well as a series of HCV nucleoside polymerase inhibitors and HIV integrase inhibitors.
This nucleoside analogue appears under certain conditions to be superior to gemcitabine with the added advantage of oral bioavailability.
In the field of systemic cancer treatment, Matrix is developing tezacitabine (FMdC), a next-generation nucleoside analogue for the treatment of solid tumors and hematologic malignancies.
This trial provides an opportunity to assess the cellular pharmacology of this novel nucleoside analogue, which is an important step toward providing guidance for optimizing dose and schedule for future trials," said Dr.
Findings from the Atlantic study indicate that VIRAMUNE + two nucleoside analogues has shown comparable efficacy to a protease inhibitor + two nucleoside analogues.
Judy Chiao, Cyclacel's VP Clinical Development and Regulatory Affairs, said, "CYC682 is a novel nucleoside analogue that acts by a unique mechanism of inhibiting DNA synthesis and triggering cell checkpoint machinery to arrest cell cycle progression.
4 /PRNewswire/ -- SciClone Pharmaceuticals (Nasdaq: SCLN) today announced the results of a Phase 2 clinical trial in chronic hepatitis B patients of its ZADAXIN(R) thymosin alpha 1 plus famciclovir, a nucleoside analogue.
These patients had previously been treated only with monotherapy or combinations of nucleoside analogue drugs and in a few cases with nonnucleoside reverse transcriptase inhibitors.
Indinavir, the new drug, received accelerated approval late yesterday for use alone or in combination with nucleoside analogue medications, such as AZT, in people with HIV or AIDS.

Full browser ?